miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression

Susheng Miao; Xionghui Mao; Shu Zhao; Kaibin Song; Cheng Xiang; Yuanjing Lv; Huanyv Jiang; Lei Wang; Baojun Li; Xianguang Yang; Zhennan Yuan; Cheng Xiu; Hongxue Meng; Ji Sun

doi:10.18632/oncotarget.19121

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression

Susheng Miao, Xionghui Mao, Shu Zhao, Kaibin Song, Cheng Xiang, Yuanjing Lv, Huanyv Jiang, Lei Wang, Baojun Li, Xianguang Yang, Zhennan Yuan, Cheng Xiu, Hongxue Meng and Ji Sun _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:62143-62153. https://doi.org/10.18632/oncotarget.19121

Metrics: PDF 1623 views | HTML 2495 views | ?

Abstract

Susheng Miao1,*, Xionghui Mao1,*, Shu Zhao3, Kaibin Song1, Cheng Xiang1, Yuanjing Lv1, Huanyv Jiang1, Lei Wang1, Baojun Li1, Xianguang Yang1, Zhennan Yuan1, Cheng Xiu1, Hongxue Meng2 and Ji Sun1

1Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China

2Department of Pathology, Harbin Medical University Cancer Hospital, Harbin 150081, China

3Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China

*These authors have contributed equally to the work

Correspondence to:

Hongxue Meng, email: [email protected]

Ji Sun, email: [email protected]

Keywords: laryngeal cancer, metastasis, mir-217, AEG-1, PD-L1

Received: September 26, 2016 Accepted: April 14, 2017 Published: July 10, 2017

ABSTRACT

High incidences of laryngeal cancer have been reported recently. Increasing our understanding of the molecular mechanisms underlying this malignancy could reveal more effective approaches to treating laryngeal cancer patients and so improve their prognoses. In this study, we explored the biological effects of miR-217 on laryngeal cancer. miR-217 potently inhibited multiple metastatic traits, including cell migration, invasion, proliferation, apoptosis, and EMT, as well as angiogensis. These effects were achieved through downregulation of the miR-217 target gene, AEG-1 and PD-L1. Clinical expression and animal model studies further confirmed our results. These findings provide new insight into the physiological effects of miR-217 in laryngeal cancer and its potential therapeutic use.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19121

Publication Alerts

Research Papers:

miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression

Abstract